Fed. Circ. Judge Skeptical Amgen Cholesterol Drug IP Is Valid
A Federal Circuit judge told an attorney Wednesday he faced an "uphill battle" in showing two Amgen patents on cholesterol-lowering drug Repatha are valid, casting doubt on the biopharmaceutical giant's closely...To view the full article, register now.
Already a subscriber? Click here to view full article